APA (7th ed.) Citation

Georgoula, C., Ferrin, M., Pietraszczyk-Kedziora, B., Hervas, A., Marret, S., Oliveira, G., . . . Fuentes, J. (2023). A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics. Child Psychiatry & Human Development, 54(5), 1360. https://doi.org/10.1007/s10578-022-01328-5

Chicago Style (17th ed.) Citation

Georgoula, Christina, et al. "A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics." Child Psychiatry & Human Development 54, no. 5 (2023): 1360. https://doi.org/10.1007/s10578-022-01328-5.

MLA (9th ed.) Citation

Georgoula, Christina, et al. "A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics." Child Psychiatry & Human Development, vol. 54, no. 5, 2023, p. 1360, https://doi.org/10.1007/s10578-022-01328-5.